Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Atlassian
TEAM
|
+$437M |
| 2 |
AbbVie
ABBV
|
+$380M |
| 3 |
Workday
WDAY
|
+$366M |
| 4 |
Synopsys
SNPS
|
+$323M |
| 5 |
Advanced Micro Devices
AMD
|
+$286M |
Top Sells
| 1 |
Adobe
ADBE
|
+$1.71B |
| 2 |
Apple
AAPL
|
+$984M |
| 3 |
Boston Scientific
BSX
|
+$642M |
| 4 |
Microsoft
MSFT
|
+$599M |
| 5 |
Texas Instruments
TXN
|
+$491M |
Sector Composition
| 1 | Technology | 31.62% |
| 2 | Healthcare | 18.99% |
| 3 | Consumer Discretionary | 10.82% |
| 4 | Financials | 10.24% |
| 5 | Industrials | 8.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1026
Western Union
WU
$2.74B
| $4.58M | ﹤0.01% |
244,632
-119,944
| -33% | -$2.25M |
|
|
TSC
1027
DELISTED
TriState Capital Holdings, Inc.
TSC
| $4.56M | ﹤0.01% |
+137,414
| New | +$4.56M |
|
1028
Textron
TXT
$14.5B
| $4.55M | ﹤0.01% |
61,112
+40,224
| +193% | +$2.99M |
|
1029
Check Point Software Technologies
CHKP
$21.2B
| $4.54M | ﹤0.01% |
32,837
-2,900
| -8% | -$401K |
|
1030
Fair Isaac
FICO
$36.5B
| $4.53M | ﹤0.01% |
9,700
-40,603
| -81% | -$18.9M |
|
|
ICVX
1031
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $4.5M | ﹤0.01% |
639,590
-1,207,070
| -65% | -$8.5M |
|
1032
Ciena
CIEN
$18.5B
| $4.5M | ﹤0.01% |
74,217
-13,775
| -16% | -$835K |
|
1033
Fortis
FTS
$24.8B
| $4.5M | ﹤0.01% |
90,876
| – | – |
|
1034
Tango Therapeutics
TNGX
$743M
| $4.44M | ﹤0.01% |
588,783
+51,682
| +10% | +$390K |
|
1035
Ventas
VTR
$31.6B
| $4.42M | ﹤0.01% |
71,622
-1,694,678
| -96% | -$105M |
|
1036
Carnival Corp
CCL
$43.6B
| $4.4M | ﹤0.01% |
+217,353
| New | +$4.4M |
|
1037
Chart Industries
GTLS
$8.96B
| $4.38M | ﹤0.01% |
25,509
+18,187
| +248% | +$3.12M |
|
1038
Compass Therapeutics
CMPX
$592M
| $4.33M | ﹤0.01% |
3,193,294
+1,720,683
| +117% | +$2.33M |
|
1039
Cardiff Oncology
CRDF
$138M
| $4.32M | ﹤0.01% |
1,742,123
-1,780,889
| -51% | -$4.42M |
|
1040
DocuSign
DOCU
$16.3B
| $4.29M | ﹤0.01% |
40,022
-21,237
| -35% | -$2.28M |
|
1041
Rogers Communications
RCI
$19.3B
| $4.29M | ﹤0.01% |
75,640
+1,098
| +1% | +$62.2K |
|
1042
10x Genomics
TXG
$1.6B
| $4.27M | ﹤0.01% |
56,111
-201,499
| -78% | -$15.3M |
|
1043
AirSculpt Technologies
AIRS
$381M
| $4.25M | ﹤0.01% |
311,523
-24,026
| -7% | -$328K |
|
1044
Larimar Therapeutics
LRMR
$352M
| $4.22M | ﹤0.01% |
1,045,245
+310,133
| +42% | +$1.25M |
|
1045
Norwegian Cruise Line
NCLH
$12.2B
| $4.22M | ﹤0.01% |
192,699
-52,719
| -21% | -$1.15M |
|
1046
Amkor Technology
AMKR
$6.2B
| $4.19M | ﹤0.01% |
193,125
-75,763
| -28% | -$1.65M |
|
1047
Jefferies Financial Group
JEF
$13.9B
| $4.17M | ﹤0.01% |
132,844
-170,645
| -56% | -$5.36M |
|
1048
Charles River Laboratories
CRL
$7.66B
| $4.17M | ﹤0.01% |
14,673
+8,421
| +135% | +$2.39M |
|
1049
PPL Corp
PPL
$26.7B
| $4.16M | ﹤0.01% |
145,700
-215,320
| -60% | -$6.15M |
|
1050
Grand Canyon Education
LOPE
$5.87B
| $4.16M | ﹤0.01% |
42,827
-3,549
| -8% | -$345K |
|